drug
AG-236
Phase 1updated 3mo agoby $AGIO AGIOS PHARMACEUTICALS, INC.
Phase 1community read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying AG-236
News(2)
- Silence causes uproar in rare blood cancer space as data sets high bar for competitorsThe mid-stage win of Silence Therapeutics’ siRNA drug in polycythemia vera validates the therapeutic approach of similar assets in development—but also sets a high standard for therapies from Taked…biospace · 9d ago
- Agios axes next-gen sickle cell candidate after it fails to best Novo’s assetAgios Pharmaceuticals’ sickle cell disease candidate didn’t prove any better than Novo Nordisk’s investigational PK activator or the biopharma’s own asset that is currently under FDA review for the…biospace · 1mo ago
Data sources
last refreshed 35m ago
Found something off?
comments(0)
5-min edit window · permanent after that